Discrepancies between primary tumor and metastasis: A literature review on clinically established biomarkers

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 3, 2012, Pages 301-313

  Vignot, Stéphane ^a   Besse, Benjamin ^b   André, Fabrice ^b   Spano, Jean Philippe ^a   Soria, Jean Charles ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Universite Paris Sud   (France)

Author keywords

Discrepancies; Metastasis; Personalized oncology; Primary tumor

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CETUXIMAB; ERLOTINIB; GEFITINIB; LAPATINIB; PANITUMUMAB; TRASTUZUMAB;

BREAST CANCER; CANCER TISSUE; COLON CANCER; DRUG RESPONSE; GENE EXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; PERSONALIZED MEDICINE; PREDICTION; PRIMARY TUMOR; REVIEW; SOLID TUMOR; TUMOR BIOPSY;

HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM METASTASIS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870383180     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.05.002     Document Type: Review

References (113)

1. Tapia C., Savic S., Wagner U., et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Research 2007, 9(3):R31.
2. Guarneri V., Giovannelli S., Ficarra G., et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. The Oncologist 2008, 13(8):838-844.
3. Simmons C., Miller N., Geddie W., et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Annals of Oncology 2009, 20(9):1499-1504.
4. Liedtke C., Broglio K., Moulder S., et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Annals of Oncology 2009, 20(12):1953-1958.
5. Hoefnagel L.D., van de Vijver M.J., van Slooten H.J., et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Research 2010, 12(5):R75.
6. Thompson A.M., Jordan L.B., Quinlan P., et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Research 2010, 12(6):R92.
7. Karlsson E., Lindstrom L.S., Wilking U., Skoog L., Johansson U., Bergh J. Discordance in hormone receptor status in breast cancer during tumor progression. American society of clinical oncology proceedings 2010, 1009.
8. Gong Y., Han E.Y., Guo M., Pusztai L., Sneige N. Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy. Cancer 2011, 117(4):705-713.
9. Curigliano G., Bagnardi V., Viale G., et al. Should liver metastases of breast cancer be biopsied to improve treatment choice?. Annals of Oncology 2011.
10. Chang H.J., Han S.W., Oh D.Y., et al. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Japanese Journal of Clinical Oncology 2011, 41(5):593-599.
11. Brogi E., Murphy C.G., Johnson M.L., et al. Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. Annals of Oncology 2011, 22(December (12)):2597-2603.
12. Niikura N., Liu J., Hayashi N., et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. Journal of Clinical Oncology 2011.
13. Amir E., Miller N., Geddie W., et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. Journal of Clinical Oncology 2011.
14. Lorincz T., Toth J., Badalian G., Timar J., Szendroi M. HER-2/neu genotype of breast cancer may change in bone metastasis. Pathology Oncology Research 2006, 12(3):149-152.
15. Amir E., Clemons M., Purdie C.A., et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treatment Reviews 2011.
16. Barbier A., Domont J., Magne N., et al. Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab. Bulletin du Cancer 2010, 97(2):E9-E15.
17. Italiano A., Saint-Paul M.C., Caroli-Bosc F.X., et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Annals of Oncology 2005, 16(9):1503-1507.
18. Chung K.Y., Shia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. Journal of Clinical Oncology 2005, 23(9):1803-1810.
19. Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Research 2006, 66(8):3992-3995.
20. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008, 26(10):1626-1634.
21. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine 2008, 359(17):1757-1765.
22. Neumann J., Zeindl-Eberhart E., Kirchner T., Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathology, Research and Practice 2009, 205(12):858-862.
23. Etienne-Grimaldi M.C., Formento J.L., Francoual M., et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clinical Cancer Research 2008, 14(15):4830-4835.
24. Artale S., Sartore-Bianchi A., Veronese S.M., et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. Journal of Clinical Oncology 2008, 26(25):4217-4219.
25. Santini D., Loupakis F., Vincenzi B., et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. The Oncologist 2008, 13(12):1270-1275.
26. Molinari F., Martin V., Saletti P., et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. British Journal of Cancer 2009, 100(7):1087-1094.
27. Garm Spindler K.L., Pallisgaard N., Rasmussen A.A., et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Annals of Oncology 2009, 20(5):879-884.
28. Loupakis F., Pollina L., Stasi I., et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Journal of Clinical Oncology 2009, 27(16):2622-2629.
29. Cejas P., Lopez-Gomez M., Aguayo C., et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PloS One 2009, 4(12):e8199.
30. Mariani P., Lae M., Degeorges A., et al. Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. Anticancer Research 2010, 30(10):4229-4235.
31. Baldus S.E., Schaefer K.L., Engers R., Hartleb D., Stoecklein N.H., Gabbert H.E. Prevalence and heterogeneity of KRAS BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clinical Cancer Research 2010, 16(3):790-799.
32. Italiano A., Hostein I., Soubeyran I., et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Annals of Surgical Oncology 2010, 17(5):1429-1434.
33. Knijn N., Mekenkamp L.J., Klomp M., et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. British Journal of Cancer 2011, 104(6):1020-1026.
34. Watanabe T., Kobunai T., Yamamoto Y., et al. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Diseases of the Colon and Rectum 2011, 54(9):1170-1178.
35. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England Journal of Medicine 2011, 364(26):2507-2516.
36. Prahallad A., Sun C., Huang S., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483(7387):100-103.
37. Bokemeyer C., Cutsem E.V., Rougier P., et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. European Journal of Cancer 2012.
38. Ellis P.M., Blais N., Soulieres D., et al. A systematic review and canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. Journal Of Thoracic Onocology 2011.
39. Keedy V.L., Temin S., Somerfield M.R., et al. American society of clinical oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. Journal of Clinical Oncology 2011, 29(15):2121-2127.
40. Matsumoto S., Takahashi K., Iwakawa R., et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. International Journal of Cancer 2006, 119(6):1491-1494.
41. Kalikaki A., Koutsopoulos A., Trypaki M., et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. British Journal of Cancer 2008, 99(6):923-929.
42. Schmid K., Oehl N., Wrba F., Pirker R., Pirker C., Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clinical Cancer Research 2009, 15(14):4554-4560.
43. Gow C.H., Chang Y.L., Hsu Y.C., et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Annals of Oncology 2009, 20(4):696-702.
44. Park S., Holmes-Tisch A.J., Cho E.Y., et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. Journal Of Thoracic Onocology 2009, 4(7):809-815.
45. Cortot A.B., Italiano A., Burel-Vandenbos F., Martel-Planche G., Hainaut P. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer 2010, 116(11):2682-2687.
46. Sun L., Zhang Q., Luan H., Zhan Z., Wang C., Sun B. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. Journal of Experimental and Clinical Cancer Research 2011, 30:30.
47. Han H.S., Eom D.W., Kim J.H., et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clinical Lung Cancer 2011, 12(6):380-386.
48. Pirker R., Pereira J.R., von Pawel J., et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. The Lancet Oncology 2012, 13(1):33-42.
49. Italiano A., Vandenbos F.B., Otto J., et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Annals of Oncology 2006, 17(6):981-985.
50. Bozzetti C., Tiseo M., Lagrasta C., et al. Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites. Journal Of Thoracic Onocology 2008, 3(1):18-22.
51. Daniele L., Cassoni P., Bacillo E., et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. Journal Of Thoracic Onocology 2009, 4(6):684-688.
52. Monaco S.E., Nikiforova M.N., Cieply K., Teot L.A., Khalbuss W.E., Dacic S. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Human Pathology 2010, 41(1):94-102.
53. Badalian G., Barbai T., Raso E., Derecskei K., Szendroi M., Timar J. Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status. Pathology Oncology Research 2007, 13(2):99-104.
54. Cappuzzo F., Hirsch F.R., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. Journal of the National Cancer Institute 2005, 97(9):643-655.
55. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England Journal of Medicine 2010, 363(18):1693-1703.
56. Kim H. Detection of ALK gene rearrangement in non-small-cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. 14th World Conference on Lung Cancer 2011.
57. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nature Reviews 2002, 2(8):563-572.
58. Baum B., Settleman J., Quinlan M.P. Transitions between epithelial and mesenchymal states in development and disease. Seminars in Cell & Developmental Biology 2008, 19(3):294-308.
59. Hugo H., Ackland M.L., Blick T., et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. Journal of Cellular Physiology 2007, 213(2):374-383.
60. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews Molecular Cell Biology 2006, 7(2):131-142.
61. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Developmental Cell 2008, 14(6):818-829.
62. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews 2009, 9(4):265-273.
63. Collins V.P., Loeffler R.K., Tivey H. Observations on growth rates of human tumors. The American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine 1956, 76(5):988-1000.
64. Spratt J.S., Meyer J.S., Spratt J.A. Rates of growth of human neoplasms: Part II. Journal of Surgical Oncology 1996, 61(1):68-83.
65. Spratt J.S., Spratt T.L. Rates of growth of pulmonary metastases and host survival. Annals of Surgery 1964, 159:161-171.
66. Kusama S., Spratt J.S., Donegan W.L., Watson F.R., Cunningham C. The cross rates of growth of human mammary carcinoma. Cancer 1972, 30(2):594-599.
67. Finlay I.G., Meek D., Brunton F., McArdle C.S. Growth rate of hepatic metastases in colorectal carcinoma. The British Journal of Surgery 1988, 75(7):641-644.
68. Pence J.C., Kizilbash A.M., Kerns B.J., Marks J.R., Iglehart J.D. Proliferation index in various stages of breast cancer determined by Ki-67 immunostaining. Journal of Surgical Oncology 1991, 48(1):11-20.
69. Bolin S., Nilsson E., Sjodahl R. Carcinoma of the colon and rectum - growth rate. Annals of Surgery 1983, 198(2):151-158.
70. Cheng L., Pisansky T.M., Sebo T.J., et al. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clinical Cancer Research 1999, 5(10):2820-2823.
71. Cheville J.C., Tindall D., Boelter C., et al. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 2002, 95(5):1028-1036.
72. Mani S.A., Guo W., Liao M.J., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4):704-715.
73. Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T., Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nature Reviews 2005, 5(9):744-749.
74. Monteiro J., Fodde R. Cancer stemness and metastasis: therapeutic consequences and perspectives. European Journal of Cancer 2010, 46(7):1198-1203.
75. Mimeault M., Batra S.K. New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histology and Histopathology 2010, 25(8):1057-1073.
76. Klein C.A. Parallel progression of primary tumours and metastases. Nature Reviews 2009, 9(4):302-312.
77. Cairns J. Mutation selection and the natural history of cancer. Nature 1975, 255(5505):197-200.
78. Navin N., Kendall J., Troge J., et al. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472(7341):90-94.
79. Ly B.H., Nguyen N.P., Vinh-Hung V., Rapiti E., Vlastos G. Loco-regional treatment in metastatic breast cancer patients: is there a survival benefit?. Breast Cancer Research and Treatment 2010, 119(3):537-545.
80. Neill M.G., Jewett M.A. The once and future role of cytoreductive nephrectomy. Urologic Oncology 2008, 26(4):346-352.
81. Spahn M., Kneitz S., Scholz C.J., et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. International Journal of Cancer 2010, 127(2):394-403.
82. Peng X., Guo W., Liu T., et al. Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PloS One 2011, 6(5):e20341.
83. Nassar A., Radhakrishnan A., Cabrero I.A., Cotsonis G.A., Cohen C. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Applied Immunohistochemistry and Molecular Morphology 2010, 18(5):433-441.
84. Buob D., Fauvel H., Buisine M.P., et al. The complex intratumoral heterogeneity of colon cancer highlighted by laser microdissection. Digestive Diseases and Sciences 2011.
85. Harris G.C., Denley H.E., Pinder S.E., et al. Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. The American Journal of Surgical Pathology 2003, 27(1):11-15.
86. Bruening W., Fontanarosa J., Tipton K., Treadwell J.R., Launders J., Schoelles K. Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions. Annals of Internal Medicine 2010, 152(4):238-246.
87. Lebeau A., Turzynski A., Braun S., et al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. Journal of Clinical Oncology 2010, 28(20):3264-3270.
88. Taillade L., Penault-Llorca F., Boulet T., et al. Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Annals of Oncology 2007, 18(6):1043-1050.
89. Goranova T.E., Ohue M., Shimoharu Y., Kato K. Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clinical & Experimental Metastasis 2011, 28(5):427-435.
90. Bueno-de-Mesquita J.M., Nuyten D.S., Wesseling J., van Tinteren H., Linn S.C., van de Vijver M.J. The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Annals of Oncology 2010, 21(1):40-47.
91. Sauter G., Lee J., Bartlett J.M., Slamon D.J., Press M.F. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. Journal of Clinical Oncology 2009, 27(8):1323-1333.
92. Hammond M.E., Hayes D.F., Dowsett M., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Archives of Pathology & Laboratory Medicine 2010, 134(6):907-922.
93. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England Journal of Medicine 2012, 366(10):883-892.
94. Gerlinger M., Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. British Journal of Cancer 2010, (October):1139-1143.
95. Xiao C., Gong Y., Han E.Y., Gonzalez-Angulo A.M., Sneige N. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. Annals of Oncology 2011, 22(July (7)):1547-1553.
96. Montagut C., Dalmases A., Bellosillo B., et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nature Medicine 2012, 18(2):221-223.
97. Rosell R., Moran T., Queralt C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. The New England Journal of Medicine 2009, 361(10):958-967.
98. Gonzalez-Angulo A.M., Hennessy B.T., Mills G.B. Future of personalized medicine in oncology: a systems biology approach. Journal of Clinical Oncology 2010, 28(16):2777-2783.
99. Strausberg R.L., Simpson A.J. Whole-genome cancer analysis as an approach to deeper understanding of tumour biology. British Journal of Cancer 2010, 102(2):243-248.
100. Tang X., Kim E., Alden C., et al. Feasibility and adequacy of molecular biomarkers analysis from core needle biopsies in lung cancer: toward personalized targeted therapy development. American Association for Cancer Research Proceedings 2009, 744.
101. Kim E.S., Herbst R.S., Wistuba I.I., et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discovery 2011.
102. Gomez-Roca C.A., Lacroix L., Massard C., et al. Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. Annals of Oncology 2012, 23(5):1301-1306.
103. de Bazelaire C., Farges C., Mathieu O., et al. Blunt-tip coaxial introducer: a revisited tool for difficult CT-guided biopsy in the chest and abdomen. American Journal of Roentgenology 2009, 193(2):W144-W148.
104. de Kerviler E., Benet C., Briere J., de Bazelaire C. Image-guided needle biopsy for diagnosis and molecular biology in lymphomas. Best Practice and Research. Clinical Haematology 2012, 25(1):29-39.
105. Lennon S., Barton C., Banken L., et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. Journal of Clinical Oncology 2009, 27(10):1685-1693.
106. Leary A.F., Hanna W.M., van de Vijver M.J., et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. Journal of Clinical Oncology 2009, 27(10):1694-1705.
107. Pantel K., Alix-Panabieres C., Riethdorf S. Cancer micrometastases. Nature Reviews. Clinical Oncology 2009, 6(6):339-351.
108. Sieuwerts A.M., Mostert B., Bolt-de Vries J., et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clinical Cancer Research 2011, 17(11):3600-3618.
109. Ignatiadis M., Rothe F., Chaboteaux C., et al. HER2-positive circulating tumor cells in breast cancer. PloS One 2011, 6(1):e15624.
110. Pestrin M., Bessi S., Galardi F., et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Research and Treatment 2009, 118(3):523-530.
111. Klein C.A. The systemic progression of human cancer: a focus on the individual disseminated cancer cell - the unit of selection. Advances in Cancer Research 2003, 89:35-67.
112. Tolmachev V., Stone-Elander S., Orlova A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. The Lancet Oncology 2010, 11(10):992-1000.
113. Andre F., Delaloge S., Soria J.C. Biology-driven phase II trials: what is the optimal model for molecular selection?. Journal of Clinical Oncology 2011.